Search Results - Popat, Rakesh

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case seri... by Popat, Rakesh, Warcel, Dana, O’Nions, Jenny, Cowley, Anna, Smith, Sasha, Tucker, William R, Yong, Kwee, Esposti, Simona Degli

Get full text Get full text Get full text

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma by Prawitz, Thibaud, Popat, Rakesh, Suvannasankha, Attaya, Sarri, Grammati, Hughes, Rachel, Wang, Feng, Hogea, Cosmina, Ferrante, Shannon Allen, Gorsh, Boris, Willson, Jenny, Kapetanakis, Venediktos

Get full text Get full text Get full text

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response by Latifoltojar, Arash, Hall‐Craggs, Margaret, Rabin, Neil, Popat, Rakesh, Bainbridge, Alan, Dikaios, Nikolaos, Sokolska, Magdalena, Rismani, Ali, D'Sa, Shirley, Punwani, Shonit, Yong, Kwee

Get full text Get full text Get full text

A Phase I trial of talazoparib in patients with advanced hematologic malignancies by Gopal, Ajay K, Popat, Rakesh, Mattison, Ryan J, Menne, Tobias, Bloor, Adrian, Gaymes, Terry, Khwaja, Asim, Juckett, Mark, Chen, Ying, Cotter, Matthew J, Mufti, Ghulam J

Get full text Get full text Get full text

Deferred autologous stem cell transplantation in systemic AL amyloidosis by Manwani, Richa, Hegenbart, Ute, Mahmood, Shameem, Sachchithanantham, Sajitha, Kyriakou, Charalampia, Yong, Kwee, Popat, Rakesh, Rabin, Neil, Whelan, Carol, Dittrich, Tobias, Kimmich, Christoph, Hawkins, Philip, Schönland, Stefan, Wechalekar, Ashutosh

Get full text Get full text Get full text

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study by Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Hoos, Axel, Gupta, Ira, Bragulat, Veronique, He, Zangdong, Opalinska, Joanna B., Cohen, Adam D.

Get full text Get full text Get full text

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induc... by Latifoltojar, Arash, Hall-Craggs, Margaret, Bainbridge, Alan, Rabin, Neil, Popat, Rakesh, Rismani, Ali, D’Sa, Shirley, Dikaios, Nikolaos, Sokolska, Magdalena, Antonelli, Michela, Ourselin, Sebastien, Yong, Kwee, Taylor, Stuart A., Halligan, Steve, Punwani, Shonit

Get full text Get full text Get full text

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiv... by Cook, Gordon, John Ashcroft, A, Pratt, Guy, Popat, Rakesh, Ramasamy, Karthik, Kaiser, Martin, Jenner, Matthew, Henshaw, Sarah, Hall, Rachel, Sive, Jonathan, Stern, Simon, Streetly, Matthew, Bygrave, Ceri, Soutar, Richard, Rabin, Neil, Jackson, Graham H

Get full text Get full text Get full text

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma by Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh

Get full text Get full text Get full text

COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial by Camilleri, Marquita, Sive, Jonathan, Wilson, William, Pang, Gavin, Jenner, Richard, Phillips, Elizabeth, Popat, Rakesh, Ramasamy, Karthik, Bygrave, Ceri, Dadaga, Tushhar, Streetly, Matthew, Cavenagh, James, Chapman, Mike, Barrington, Sally, Pike, Lucy, Owen, Roger, Clifton‐Hadley, Laura, Yong, Kwee

Get full text Get full text Get full text

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia by Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio, Cecilia, Molinero, César, Mascaró, Cristina, Vila, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch, Francesc, Somervaille, Tim C. P.

Get full text Get full text Get full text

The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study by Camilleri, Marquita, Bekris, Georgios, Sidhu, Govundeep, Buck, Caroline, Elsden, Esma, McCourt, Orla, Horder, Jackie, Newrick, Fiona, Lecat, Catherine, Sive, Jonathan, Papanikolaou, Xenofon, Popat, Rakesh, Lee, Lydia, Xu, Ke, Kyriakou, Charalampia, Rabin, Neil, Yong, Kwee, Fisher, Abigail

Get full text Get full text Get full text

Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy by Chan, Wei Yee, Sanchez, Emilie, Chavda, Selina J., Lecat, Catherine S. Y., Ainley, Louise, Xu, Ke, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Kyriakou, Charalampia, Sive, Jonathan, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Lee, Lydia, Nastouli, Eleni, Yong, Kwee L.

Get full text Get full text Get full text

Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modifie... by Koutoukidis, Dimitrios A., Land, Joanne, Hackshaw, Allan, Heinrich, Malgorzata, McCourt, Orla, Beeken, Rebecca J., Philpott, Stephanie, DeSilva, Dunnya, Rismani, Ali, Rabin, Neil, Popat, Rakesh, Kyriakou, Charalampia, Papanikolaou, Xenofon, Mehta, Atul, Paton, Bruce, Fisher, Abigail, Yong, Kwee L.

Get full text Get full text Get full text

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma by Ramasamy, Karthik, Nooka, Ajay, Quach, Hang, Htut, Myo, Popat, Rakesh, Liedtke, Michaela, Tuchman, Sascha A., Laubach, Jacob, Gasparetto, Cristina, Chanan-Khan, Asher, Hertzberg, Mark, deMario, Mark, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Cho, Hearn Jay

Get full text Get full text Get full text

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma by Morris, Treen Carson Michael, Drake, Mary B., Kettle, Paul J., McGuigan, Tracey, Leahy, Maeve, O’Dwyer, Michael, Enright, Helen, O’Shea, Tanya, Popat, Rakesh, Oakervee, Heather E., Yong, Kwee, Cavenagh, Jamie D., Cairns, David A., Alvarez-Iglesias, Alberto, Cook, Gordon

Get full text Get full text Get full text

Targeting B-Cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma: A Dose-Escalation and Expansion Phase 1 Trial (BMA117159) by Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Anderson, Larry D., Sutherland, Heather J., Yong, Kwee, Hoos, Axel, Gorczyca, Michele M., Lahiri, Soumi, He, Zangdong, Austin, Daren J., Opalinska, Joanna B., Cohen, Adam D.

Get full text Get full text Get full text

Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study by Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn

Get full text Get full text Get full text

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study by Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn

Get full text Get full text Get full text

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma by Bruno, Benedetto, Wäsch, Ralph, Engelhardt, Monika, Gay, Francesca, Giaccone, Luisa, D’Agostino, Mattia, Rodríguez-Lobato, Luis-Gerardo, Danhof, Sophia, Gagelmann, Nico, Kröger, Nicolaus, Popat, Rakesh, van de Donk, Niels W C J, Terpos, Evangelos, Dimopoulos, Meletios A, Sonneveld, Pieter, Einsele, Hermann, Boccadoro, Mario

Get full text Get full text Get full text